^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCL19 underexpression

    i
    Other names: CCL19, C-C Motif Chemokine Ligand 19, ELC, CK Beta-11, Exodus-3, MIP-3b, SCYA19, CKb11, Small Inducible Cytokine Subfamily A (Cys-Cys), Member 19, Epstein-Barr Virus-Induced Molecule 1 Ligand Chemokine, Macrophage Inflammatory Protein 3-Beta, Chemokine (C-C Motif) Ligand 19, Small-Inducible Cytokine A19, Beta Chemokine Exodus-3, CC Chemokine Ligand 19, C-C Motif Chemokine 19, EBI1-Ligand Chemokine, MIP-3-Beta, MIP3B, Macrophage Inflammatory Protein 3 Beta, Beta-Chemokine Exodus-3, EBI1 Ligand Chemokine
    Entrez ID:
    6363
    Related biomarkers:
    Expression
    Others
    6ms
    CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers. (PubMed, Aging (Albany NY))
    In conclusion, our findings support the notion that elevated CCL19 expression is linked to favorable outcomes and enhanced anti-tumor immunity, characterized by increased CD8 T cells within the TME. This suggests the potential of CCL19 as a prognostic marker, predictive biomarker for immunotherapy, therapeutic target of cancers.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CCL19 (C-C Motif Chemokine Ligand 19)
    |
    CCL19 elevation • CCL19 underexpression